The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
New therapies for obesity
Open accessAbstract
Obesity is a chronic disease associated with serious complications and increased mortality. Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to compensatory biological adaptations (increased appetite and reduced energy expenditure) promoting weight gain. Bariatric surgery was until recently the only intervention that consistently resulted in ≥ 15% WL and maintenance. Our better understanding of the endocrine regulation of appetite has led to the development of new medications over the last decade for the treatment of obesity with main target the reduction of appetite. The efficacy of semaglutide 2.4 mg/week—the latest glucagon-like peptide-1 (GLP-1) receptor analogue—on WL for people with obesity suggests that we are entering a new era in obesity pharmacotherapy where ≥15% WL is feasible. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The effect of different weight loss interventions [low-calorie diet, exercise, pharmacotherapy (GLP-1 receptor analogues), and bariatric surgery] on appetite.](https://figures.cochat.ai/paper-figures/74f216bb7eab42a2a84eb3e4b32f20c9/new-therapies-for-obesity-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Around 10–30% of participants (especially people with T2D) achieved <10% WL in clinical trials even with the higher doses of the new pharmacotherapies [101, 102].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple other molecules (including combinations of entero-pancreatic hormones and oral GLP-1 RA) are in late phase clinical trials as potential obesity treatments, leading to WL that approaches the efficacy of bariatric surgery [101].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Despite that sleeve gastrectomy and gastric bypass, the two most commonly performed bariatric procedures today, can result in sustained long-term WL ≥ 20–25% in people with obesity and T2D and in multiple cardiometabolic benefits, bariatric surgery is an intervention which is not scalable in population level and people can be hesitant to this option due to the risk of postoperative complications [”
The cited source says what the claim attributes to it.
In the citing paper
“Despite that sleeve gastrectomy and gastric bypass, the two most commonly performed bariatric procedures today, can result in sustained long-term WL ≥ 20–25% in people with obesity and T2D and in multiple cardiometabolic benefits, bariatric surgery is an intervention which is not scalable in population level and people can be hesitant to this option due to the risk of postoperative complications [”
In the citing paper
“Despite that sleeve gastrectomy and gastric bypass, the two most commonly performed bariatric procedures today, can result in sustained long-term WL ≥ 20–25% in people with obesity and T2D and in multiple cardiometabolic benefits, bariatric surgery is an intervention which is not scalable in population level and people can be hesitant to this option due to the risk of postoperative complications [”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
Hills, A. P., Byrne, N. M., Lindstrom, R., & Hill, J. O. (2013) · Obesity Facts · doi:10.1159/000345030 · Cited by 9,493
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“68 On the other hand, in the STEP-3 study where semaglutide 2.4 mg was combined with IBT and an 8-week low-calorie diet, 15,73 the WL achieved at 68 weeks was similar to the WL reported when Semaglutide 2.4 mg was combined with a 500 kcal/day deficit diet 15 (16 vs. 14.9”
BackgroundMethodInfluentialSelf-citationProspective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 1×
“…associated with improvement in QoL and obesity-related complications, reduction by 53% in fatal and 33% in total cardiovascular events, and reduction by 29% in mortality compared with the usual care group, 11,12,46,47 providing a WL threshold associated with multiple clinically important benefits.”
BackgroundLifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“77 Other dual co-agonists acting on GLP-1/amylin receptors and GLP-1/ glucagon receptors are also being assessed in early phase clinical trials as potential treatments for obesity and metabolic complications.”
BackgroundHaslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Research works printed but not linked: 2
- Aronne, 2021, Describing the weight-reduced state: physiology, Obesity (Silver Spring, 29, S9
- De Silva, 2011, The gut hormones PYY, Cell Metab, 14, 3
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Multiple other molecules (including combinations of entero-pancreatic hormones and oral GLP-1 RA) are in late phase clinical trials as potential obesity treatments, leading to WL that approaches the ef fi cacy of bariatric surgery [101].”
Self-citationEfficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Self-citationMłynarska, E., Bojdo, K., Bulicz, A., Frankenstein, H., Gąsior, M., Kustosik, N., Rysz, J., & Franczyk, B. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100787 · Cited by 97
“Although dedicated cardiovascular outcome trials in people with obesity are still needed, current data suggest no increased cardiovascular risk [119].”
Domingo, E., Marqués, P., Francisco, V., Piqueras, L., & Sanz, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107058 · Cited by 73
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
“Similarly, lifestyle interventions are key for the management of obesity; however, even the implementation of most intensive programmes translates into 5–10% BW loss with a tendency for weight regain [31].”
Background
Metadata
- Authors
- Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J.
- Affiliations
- University of Leicester (GB)
- Diabetes Complications Research Centre, Conway Institute, University College Dublin , Dublin 4 , Ireland
- University of Copenhagen (DK)
- Corresponding author
- Papamargaritis, Dimitris
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-11-30
- Volume
- 119
- Issue
- 18
- Pages
- 2825-2842
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC10874276
- OpenAlex
- W4310416488
- Semantic Scholar
- c9c62a64b6cead4b21fbd76ca890be39591b68cc
- Cited by
- 73
- References
- 141
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 31 · 2023: 11
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Cardiovascular Research (publishedVersion, public-domain)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Ulster University Research Portal (Ulster University) (submittedVersion, public-domain)
- Figshare (submittedVersion, cc-by)
- Funders
- Leicester NIHR Biomedical Research Centre
- National Institute of Clinical Research Clinical Lectureship
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, obesity pharmacotherapy, weight loss, appetite regulation, bariatric surgery, semaglutide, GLP-1 receptor agonists, tirzepatide, glucose-dependent insulinotropic polypeptide, lifestyle intervention
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Appetite, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New therapies for obesity. https://app.cochat.ai/papers/10.1093/cvr/cvac176
- The paper
- Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024). New therapies for obesity. Cardiovascular Research. https://doi.org/10.1093/cvr/cvac176
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.